Instructions

|  |
| --- |
| ***Definition***Health technologies are broadly defined as interventions that substantially change the way care is delivered. They may take the form of a new test, device, procedure, therapy or program substantially different from the alternative. Health technologies significantly change clinical practice in the prevention, diagnosis, treatment, and/or rehabilitation of disease. |

NSW Health invites NSW Health Chief Executives and Deputy Secretaries of the NSW Ministry of Health to make submissions to the NSW Health New Technologies and Specialised Services Committee.

Submissions are required for all new and emerging health technologies that meet the eligibility criteria for statewide assessment as prescribed in the [*Guideline for New Health Technologies and Specialised Services (GL2024\_008).*](https://www1.health.nsw.gov.au/pds/Pages/doc.aspx?dn=GL2024_008)

The eligibility criteria for new or emerging health technologies include:

* The intervention is complex to deliver safely and effectively in NSW. This may include a highly skilled workforce, highly specialised infrastructure and/or procedure.
* The cost of service provision is of significance to the NSW Health system. This may include the requirement for a flexible and/or individualised purchasing approach.
* The patient volume is low and requires only selected sites to meet safety and quality outcomes and achieve service proficiency in NSW.

***General requirements for submissions:***

* All materials accompanying an application must comply with privacy and intellectual property principles and regulations
* Information identifying individual patients is not to form any part of the application
* Applicants understand that by submitting an application, all confidential, personal or proprietary information included are subject to the provisions of the [*Government Information (Public Access) Act 2009*](https://legislation.nsw.gov.au/view/html/inforce/current/act-2009-052)(NSW)
* Applicant must obtain manufacturer consent for information provided in applications submitted to NSW Ministry of Health

***Note:***

* Submissions will only be accepted following approval by the chief executive of a NSW Health Agency, Pillar, District, Network, or a Deputy Secretary of the NSW Ministry of Health.
* Completed submission forms, queries regarding completion of this form and/or general enquiries regarding new health technology processes in NSW, can be emailed to: MOH-HealthTech@health.nsw.gov.au.

1. **Contact INFORMATION**

|  |
| --- |
| **Nomination Contact** |
| **Name**  |       |
| **Position** |       |
| **Organisation** |       |
| **Address** |       |
| **Phone number** |       |
| **Email address** |       |

|  |
| --- |
| **Clinical Contact** |
| **Name**  |       |
| **Position** |       |
| **Facility and Department** |       |
| **Phone number** |       |
| **Email address** |       |

1. **General Information**
	1. **Name of Health Technology**

|  |
| --- |
|       |

* 1. **Purpose of Review**

*The health technology is being submitted to the Committee for consideration for the following reason/s (tick all that apply)*

|  |
| --- |
|[ ]  emerging technology available to NSW public patients in research with potential to significantly impact current or future clinical care in NSW  |
|[ ]  potential for broad adoption of the technology |
|[ ]  there are complexities that elevate the new health technology out of local or inter-district planning/budgeting capacity, such as specific specialised workforce/technical/infrastructure requirements or specific purchasing approach |
|[ ]  technology likely to require service concentration to meet safety and quality outcomes and achieve service proficiency in NSW |
|[ ]  current technology nominated for disinvestment or phasing down |
|  |  |

* 1. **Technology Type** *(tick all that apply)*

|  |  |  |  |
| --- | --- | --- | --- |
| [ ]  | implantable device | [ ]  | approved device for use outside approved use |
| [ ]  | medical or surgical procedure | [ ]  | device provided on a trial period by manufacturer |
| [ ]  | treatment (e.g. medicine, therapeutic) | [ ]  | gene-based markers, therapies or diagnostic |
| [ ]  | diagnostic (e.g. test) | [ ]  | clinical practice / pathway |

 *Comments*

|  |  |
| --- | --- |
|  |       |

* 1. **Is the Technology currently available to NSW Public Patients?**

|  |  |  |  |
| --- | --- | --- | --- |
| [ ]  | Yes* *summarise how the technology is being delivered*
	+ *i.e. special access scheme, clinical trial, non-clinical trial*
* *current volumes and outcomes.*
 | [ ]  | No* *summarise current availability and reasons why public access is not provided.*
 |
|  *250 words max*

|  |
| --- |
|       |

 |

* 1. **TGA Approved for the Specific Clinical Scenario?**

|  |  |  |  |
| --- | --- | --- | --- |
| [ ]  | Yes* *reference number*
 | [ ]  | No* *describe regulatory status, including anticipated timeframe for Therapeutic Goods Administration approval and any international approvals*
* *specify the condition(s) that will be treated by the technology*
 |
|  |       |
|  |
|  |  |  |  |       |

1. **New Health technology overview**

*Brief description of the new technology:*

* *Target population and clinical indication*
* *Comparator technology*
* *Expected outcomes – this should include a discussion on the safety, efficacy and
cost-effectiveness of the new technology in comparison to the current standard of care*
* *Results of local implementation*
* *Impact of the technology on other services both short and long term.*

 *500 words max*

|  |
| --- |
|       |

1. **NEW TECHNOLOGY OVERVIEW**
	1. **Patient Population(s) and Projected Demand**

*Describe (as appropriate):*

* *Incidence and prevalence in NSW of the target disease*
* *Years of Life Lost and Disability Adjusted Life Years*
* *Patient catchment, demographic, population and* *patient selection criteria*
* *Anticipated annual volume and 5-10 year growth projections.*

|  |
| --- |
|       |

1. **Literature and Evidence**

*Summarise available evidence using the modified PICO table below:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Reference** | **Study Type** | **Population** | **Intervention and Control** | **Outcomes** |
|       |       |       |       |       |
|       |       |       |       |       |
|       |       |       |       |       |
|       |       |       |       |       |
|       |       |       |       |       |
|       |       |       |       |       |
|       |       |       |       |       |
|       |       |       |       |       |
|       |       |       |       |       |
| **Analysis of ALL papers**(200 words max) |       |

 *Example*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Reference** | **Study Type** | **Population** | **Intervention and Control** | **Outcomes** |
| Researcher et. al., A Journal 2018 | Double blind randomised controlled trial | Adults with metastatic small cell lung cancer | Guided ultrasound radiotherapy vs intraoperative radiotherapy | 5% reduction in absolute risk of all-cause mortality over 10 years |
| **Analysis of ALL papers**(200 words max) | Provide a brief analysis of the quality of the available evidence in relation to the target population. This should take into account study limitations, inconsistency in results, bias, indirectness of evidence and overall results. Consider using an established method to assess quality of evidence such as NH&MRC and/or GRADE. |

**5. Disinvestment and/or offset opportunities**

*Describe (as appropriate):*

* *Opportunities for disinvestment/offset and/or system savings*
* *If the technology is in addition to or replacement of current technology*
* *Impact on patient transfers between facilities.*

|  |
| --- |
|       |

**6. Financial and workforce implications**

*Describe (as appropriate):*

* *Anticipated financial impact, including estimated annual operating costs (when fully operational), offsets, net recurrent impact and capital requirements*
* *Opportunities for system efficiencies or cost savings*
* *Support and training requirements*
* *Time required per case and impact on staffing*
* *Training requirements.*

|  |
| --- |
|       |

**7. Environmental impact**

*Describe (as appropriate):*

* *Anticipated environmental impact of the technology*
* *Opportunities to support NSW Health transition to a net zero health system (e.g., clean energy, energy efficiency, sustainable transportation, and water conservation).*

|  |
| --- |
|       |

**8. Risk assessment**

*Detail of your risk assessment and management plan*

|  |
| --- |
|       |

**9. Other**

*Provide or attach any additional information you would like considered*

|  |
| --- |
|       |

**10. Conflicts of Interest**

*List of conflicts (as appropriate)*

|  |
| --- |
|       |

**11. Sharing of information**

*The Ministry would like to share a summary of this emerging technology update on the New Health Technologies webpages; housed on the NSW Health Intranet. The purpose of this is to increase the knowledge in the system and to facilitate collaboration.*

*Following the assessment process the Ministry will draft a summary of the technology. The summary will not be shared without approval from the chief executive.*

*Final sign off for any content will sit with the Deputy Secretary, Strategy and Resources.*

 *Circle approval*

|  |
| --- |
|  **I consent / do not consent** to the Ministry sharing an approved summary of this update |

**12. CHIEF EXECUTIVE DECLARATION**

*I confirm the accuracy of the above information and consider that the nomination meets the criteria for consideration through NSW Health’s new health technology evaluation processes.*

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Click or tap to enter a date.

Signed (Chief Executive / Deputy Secretary) Date

Email completed nomination form to: MOH-HealthTech@health.nsw.gov.au